The Leadless Pacing System Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
New York, NY -- (SBWIRE) -- 04/04/2017 -- Catheter is a small device, tube-like structure that is used to perform the various surgical procedure and also helps in the treatment of different diseases. For many years, cardiac pacing has been achieved with the surgically implanted subcutaneous electrical generator connected with transvenous leads, which provides pacing therapy to the heart but some showed complications with subcutaneous pocket, lead-insertion problems, lead dislodgements and integrity problems, infections such as septicemia and endocarditis and vascular obstructions. Due to the associated complications, the option for leadless pacing system is gaining interest.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12205
Micra leadless pacing system is manufactured by Medtronic plc. Leadless pacing system is used to treat indications such as heart arrhythmia, atrial fibrillation, and other complicated arrhythmias. Leadless pacing system is a full featured single chamber ventricular pacemaker, which is implanted in the right ventricle. The device is affixed through four electrically inactive nitinol tines at the distal end. Leadless pacing system uses invasive approach and is delivered percutaneous, without the use of leads. Leadless pacing system helps to have a regular heartbeat. Leadless pacing system is smaller than a traditional pacemaker and delivers on average 12-year battery longevity. Leadless pacing system is 105-cm long, which controls the position of the micra pacing capsule. It has a silicone oil-coated dilator tip.
Nanostim leadless pacemaker system is manufactured by St. Jude Medical and is a single chamber rate-responsive pacemakers. It is indicated for patients with normal sinus rhythm with rare episodes of A-V block or sinus arrest; bradycardia, etc. Leadless pacing system is designed to avoid the need for a transvenous lead and a pacemaker pocket. Leadless pacing system has advantage over traditional pacemaker as it can be left implanted once it has reached battery depletion.
The demand for leadless pacing system will be fuelled by increased burden of arrhythmias cases. The incidence of heart arrhythmia is growing in developed countries. According to American College of Cardiology Foundation, approximately 200,000 pacemakers are implanted in the United States each year. In the U.K., the most common type of heart surgery carried out is pacemaker implantation.
Worldwide a gradual increase in heart surgical procedures along with aging population is the major factor to fuel the growth of the global leadless pacing system market during the forecast period. Increase collaboration among the major global players to develop the novel products, is one of the major trends in the global leadless pacing system market. However, high research and development expenses in product development and the low awareness about leadless pacemaker treatments in the developing countries is anticipated to hamper the growth of leadless pacing systems market over the forecast period.
According to the U.S. Food and Drug Administration, nearly 1 million people worldwide are implanted with pacemakers each year. In 2012, 17.5 million people died from cardiovascular diseases. Hospital segment is expected to contribute maximum revenue share among end users segments. According to Centers for Disease Control and Prevention, 2.7–6.1 million people have atrial fibrillation in the United States. This number is expected to increase with the aging population. African Americans are less likely to have atrial fibrillation than those of European descent. Prevalence of atrial fibrillation is more in women compare to men.
On the basis of regional presence, global leadless pacing system market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America is estimated to dominate the global leadless pacing system market due to the high incidence of atrial fibrillation and adequate reimbursement policies.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/12205
Some of the players in global leadless pacing system market are Medtronic, St. Jude Medical, Boston Scientific, BIOTRONIK, etc.